Improved functionalization of oleic acid-coated iron oxide nanoparticles for biomedical applications

Superparamagnetic iron oxide nanoparticles can providemultiple benefits for biomedical applications in aqueous environments such asmagnetic separation or magnetic resonance imaging. To increase the colloidal stability and allow subsequent reactions, the introduction of hydrophilic functional groups onto the particles’ surface is essential. During this process, the original coating is exchanged by preferably covalently bonded ligands such as trialkoxysilanes. The duration of the silane exchange reaction, which commonly takes more than 24 h, is an important drawback for this approach. In this paper, we present a novel method, which introduces ultrasonication as an energy source to dramatically accelerate this process, resulting in high-quality waterdispersible nanoparticles around 10 nmin size. To prove the generic character, different functional groups were introduced on the surface including polyethylene glycol chains, carboxylic acid, amine, and thiol groups. Their colloidal stability in various aqueous buffer solutions as well as human plasma and serum was investigated to allow implementation in biomedical and sensing applications.status: publishe

Usability and effectiveness of auditory sensory substitution models for the visually impaired

This paper focuses on auditory sensory substitution for providing visually impaired users with suitable information in both static scene recognition and dynamic obstacle avoidance. We introduce three different sonification models together with three temporal presentation schemes, i.e. ways of temporally organizing the sonic events in order to provide suitable information. Following an overview of the motivation and challenges behind each of the solutions, we describe their implementation and an evaluation of their relative strengths and weaknesses based on a set of experiments conducted in a virtual environment

An enhanced method for accessory pathway localization in case of Wolff-Parkinson-White syndrome

This paper presents an analysis of the Arruda accessory pathway localization method for patients suffering from Wolff-Parkinson-White syndrome, with modifications to increase the overall accuracy. The Arruda method was tested on a total of 79 cases, and 91.1% localization performance was reached. After a deeper analysis of each decision point of the Arruda localization method, we considered that the lead aVF was not as relevant as other leads (I, II, III, V1) used. The branch of the decision tree, which evaluates the left ventricle positions, was entirely replaced using different decision criteria based on the same biological parameters. The modified algorithm significantly improves the localization accuracy in the left ventricle, reaching 94.9%. An accurate localization performance of non-invasive methods is relevant because it can enlighten the necessary invasive interventions, and it also reduces the discomfort caused to the patient

Sound of vision : spatial audio output and sonification approaches

The paper summarizes a number of audio-related studies conducted by the Sound of Vision consortium, which focuses on the construction of a new prototype electronic travel aid for the blind. Different solutions for spatial audio were compared by testing sound localization accuracy in a number of setups, comparing plain stereo panning with generic and individual HRTFs, as well as testing different types of stereo headphones vs custom designed quadrophonic proximaural headphones. A number of proposed sonification approaches were tested by sighted and blind volunteers for accuracy and efficiency in representing simple virtual environments

InFutURe Wood Report 1: Design for deconstruction and reuse of timber structures – state of the art review

This report represents the first publication of the InFutURe Wood project - Innovative Design for the Future – Use and Reuse of Wood (Building) Components.InFutUReWood is supported under the umbrella of ERA-NET and financed by funding agencies from each of the participating countries. The industry partners participate mostly with in-kind.The research and academia project partners are RISE (Sweden), Edinburgh Napier University (UK), National University of Ireland Galway (Ireland), University College Dublin (Ireland), Polytechnic University of Madrid (Spain), University of Ljubljana (Slovenia), Aalto University Helsinki (Finland), and Technical University Munich (Germany).The industry partners are Kiruna Municipality Technical Service, Swedish Wood, Derome, Isotimber, Offsite Solutions Scotland, Hegarty Demolition, SIP Energy, Connaught Timber, The Federation of the Finnish Woodworking Industries, Jelovica, The Swedish Federation of Wood and Furniture Industry, Balcas Timber, Stora Enso, Klimark + Nova domus Hábitat, and Brenner Planungsgesellschaft

Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo

Background: Cardiovascular (CV) disease is the leading cause of morbidity and mortality in patients with type 2 diabetes mellitus (T2DM). Furthermore, patients with T2DM and acute coronary syndrome (ACS) have a particularly high risk of CV events. The glucagonlike peptide 1 receptor agonist, lixisenatide, improves glycemia, but its effects on CV events have not been thoroughly evaluated. Methods: ELIXA (www.clinicaltrials.gov no. NCT01147250) is a randomized, double-blind, placebo-controlled, parallelgroup, multicenter study of lixisenatide in patients with T2DM and a recent ACS event. The primary aim is to evaluate the effects of lixisenatide on CV morbidity and mortality in a population at high CV risk. The primary efficacy end point is a composite of time to CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina. Data are systematically collected for safety outcomes, including hypoglycemia, pancreatitis, and malignancy. Results: Enrollment began in July 2010 and ended in August 2013; 6,068 patients from 49 countries were randomized. Of these, 69% are men and 75% are white; at baseline, the mean ± SD age was 60.3 ± 9.7 years, body mass index was 30.2 ± 5.7 kg/m2, and duration of T2DM was 9.3±8.2 years. The qualifying ACS wasamyocardial infarctionin83% and unstableangina in 17%. The study will continue until the positive adjudication of the protocol-specified number of primary CV events. Conclusion: ELIXA will be the first trial to report the safety and efficacy of a glucagon-like peptide 1 receptor agonist in people with T2DM and high CV event risk. © 2015 Elsevier Inc. All rights reserved